Report
Damien Choplain ...
  • Martial Descoutures

Sanofi : Le T3 bénéficie des vaccins et de l’insuline

>Un T3 solide orienté par un bon phasing des envois de vaccins - Sanofi publie ce matin ses résultats du T3 24 qui s’avèrent au-dessus des attentes à la fois au niveau des ventes que de son Core BPA, malgré un l’effet changes très négatif attendu(-3.4% en topline et -5.4% en bottom line) . Brièvement, les ventes totales du groupe lors de ce T3 ressortent à 13 438 M€ vs 12 634 M€ att (+12.3% ; +15.7% à tcc), son core EBIT à 4 607M€ vs 4 032 M€ att (14.4% ; 19.9% tcc) p...
Underlying
Sanofi

Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Damien Choplain

Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch